Core Insights - Galera Therapeutics has entered into an Asset Purchase Agreement with Biossil for its dismutase mimetics portfolio, which includes avasopasem and rucosopasem formulations and indications [1][3] - The agreement entails an upfront payment of $3.5 million, with potential future regulatory and commercial milestones, and contingent value rights totaling up to $105 million [1][3] - Biossil will assume all obligations under the Royalty Agreement with Blackstone Life Sciences, which includes a 4% royalty if avasopasem or rucosopasem reaches commercialization [2][3] Company Developments - Galera's lead program is a pan-inhibitor of Nitric Oxide Synthase (NOS), currently in a multicenter Phase 2 trial for metaplastic breast cancer, in combination with alpelisib and nab-paclitaxel [2][4] - Avasopasem has shown promising results in a Phase 3 trial, demonstrating a 16% relative reduction in severe oral mucositis incidence and a 56% relative reduction in duration among patients receiving chemoradiotherapy for head and neck cancer [5] - The FDA has granted Fast Track and Breakthrough Therapy designations to avasopasem for reducing radiotherapy-induced oral mucositis [6] Strategic Implications - The agreement with Biossil is expected to enhance the prospects for avasopasem's development and commercialization, benefiting both companies and their shareholders [7] - Biossil aims to leverage its expertise and financing to advance avasopasem through clinical and regulatory challenges, addressing the urgent need for treatments that improve the tolerability of chemoradiotherapy [7][10]